Phaseline

Targets › MAGEA2

MAGEA2 (Melanoma-associated antigen 2): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2027.

Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. (UniProt, P43356)

Open in Phaseline: the race on MAGEA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
OSE ImmunotherapeuticsOSE2101
peptidic cancer vaccine with nine HLA-A2-restricted epitopes targeting tumor-associated an
TP53, ERBB2, CEA, MAGEA2, MAGEA3Phase 3Patients With Non-Small Cell Lung Cancer; Solid Advanced TumorDec 2027

Conditions

Patients With Non-Small Cell Lung Cancer (1) Solid Advanced Tumor (1)

Modalities

small molecule (1)

Companies

OSE Immunotherapeutics (1)

Related targets

TP53 (1) ERBB2 (1) CEA (1) MAGEA3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.